Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Controlled drugs

NICE publishes draft scope for new guideline on cannabis-based products for medicinal use

The National Institute for Health and Care Excellence (NICE) has published a draft scope for its upcoming guidelines on cannabis-based products for medicinal use.

The guideline scope, which is out for consultation between 13 November 2018 and 4 December 2018, is aimed primarily at healthcare professionals prescribing cannabis-based medicinal products, or those taking care of people taking cannabis-based medicinal products. 

The document considers the use of these products in line with the General Medical Council’s guidance on prescribing unlicensed medicines for people with chronic pain, intractable nausea and vomiting, spasticity and severe treatment-resistant epilepsy.

As part of this, NICE draws attention to its existing published guidance for the management of multiple sclerosis, epilepsy, cerebral palsy, Parkinson’s disease, cancer and motor neurone disease, which may be relevant.

The document notes that smoked cannabis and cannabis supplements, such as those marketed as food products, are excluded from the guideline. 

Ultimately the NICE guidance, which is due to be published in October 2019, will look at the effectiveness and safety of cannabis-based medicinal products, taking into consideration the clinical and cost effectiveness in relation to side effects, potential interactions and overall risks.

It will also look at decision-making and the support needed to help prescribers and patients make decisions about cannabis-based medicinal products, as well as the prescribing requirements, such as who should be able to prescribe and dispense these medicines.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205747

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.